Growth Factors of Cancer biomarkers Market
The cancer biomarkers market size was valued at USD 18.94 billion in 2018, and the market is now projected tgrow tUSD 97.42 billion by 2032, exhibiting a CAGR of 12.4% during the forecast period of 2019-2026.
Influenced by the disruptive effect of COVID-19 on healthcare services, the reported cancer biomarkers market saw significant implications. Telemedicine came intuse when many cancer screening procedures, diagnostic tests, and other elective procedures were deferred or stayed halted due tCovid19 surge in healthcare organisations. This reduced the demand of the cancer biomarker tests since diagnoses were delayed. On the other hand, the pandemic brought teleconsultation and digital health solutions intpractice thus easing the means of cancer care delivering. Furthermore, the enhance research spending and joint efforts tlabel pandemic relevant biomarkers boosted overall biomarker market, including cancer biomarkers with a long-term impact towards the growth of molecular diagnostics and precise medicine. This boosted the cancer biomarkers market growth.
Most of the pharmaceutical companies across the globe are interested in conducting research on new biomarkers that can be used in diagnosis and treatment of cancer. A large number of prospects are still under development and are estimated tprovide a major driver in the market in their final phases. Companion diagnostics, individualized therapy, and other diagnostic applications are the most common areas for utilizing cancer biomarkers for disease risk prediction and drug discovery. The advancement in the biomarkers used in diagnostics of diseases is one of the key trends that are likely tpropel the cancer biomarkers industry in the forecast timeline. These factors drive the cancer biomarkers market shares.
Lack of standard diagnosis and treatment of cancers forcing a shift towards personalized medicine for this ailment is one of the major factors expected tfoster demand for cancer biomarkers. Furthermore, the role of biomarkers is rising this year in the area of targeting drugs in the differential diagnosis, prognosis of diseases, and subsequent treatment. Another factor is the collaborations of various key market players with research institutes with the purpose of developing new cancer biomarkers for the concept of personalized medicine alsbelongs tmajor factors expected tboost the market growth throughout the predicted period.
Comprehensive Analysis of Cancer biomarkers Market
The cancer biomarkers market is responding quite an unprecedented rate of growth because of its market segmentation. This indicators growth in different regions by substituting the major forces of supply and demand which define the shape of local pharmacy benefit management market. Therefore, they are logically divided int3 Segments, By Cancer Type Analysis, By Biomarker Type Analysis and By End User Analysis. Whereby based on type it is sub-divided intbreast cancer, lung carcinoma, colorectal carcinoma, prostate carcinoma, and other types of cancer. Oncology biomarkers’ major segment was the breast cancer segment in 2018. Higher incidence of breast cancer alone with growing awareness of other types of breast cancer diagnosis creates great amount of patients having diagnostics tests. According tthe biomarker type, the market is further classified PSD, HER-2, EGFR, KRAS and others etc. HER-2 segment accounted the largest share in 2018 owing tgrowing incidence of breast cancer along with the awareness about the disease diagnosis in the developed and developing nations. In addition, there has been an emergence of new biomarker based tests from market players in the diagnosis of breast cancer through liquid biopsy which is spurring demand of these tests internationally. This report divides the market based on end user – Pharmaceutical & Biotechnology companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics and Others. Among the end users, the diagnostics and research laboratories was the largest segment in the cancer biomarkers market.
The market size in North America was valued at USD 6.88 billion in 2018. Some of the factors influencing higher dominance in North America include: improved usage of advanced technology such as next-generation sequencing, rising number of research and studies on how biomarkers can efficiently aid in drug R&D as well as cancer detection.
F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), ThermFisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), CENTOGENE N.V. (Germany), Axon Medchem (Netherlands), SinBiological Inc. (China), R&D System (U.S.), BioVision Inc. (U.S.), and Myriad RBM (U.S.) are significant players in the Healthcare market. They are the key player that ensures the industry's success while still having tkeep pace with their innovation in product and services. They offer a competitive zone that incites the growth of technologies and quality assurance. Some of them are big and international while others are of small scale the market players are competing in a level playing ground as they bring new products that transform the market.
In July 2020, the deal saw ThermFisher establish a companion diagnostic agreement with Chugai Pharmaceutical Co., Ltd, while applying tthe Ministry of Health, Labour and Welfare (MHLW) texpand the use of Oncomine Dx Target Test in Japan. This collaboration aims tcollaborate in steady expansion of biomarker tests on NSCLC patients for entrectinib eligibility in Japan.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2015-2026
Base Year 2018
Forecast Period 2019-2026
Historical Period 2015-2017
Unit Value (USD billion)
Segmentation By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Others
By Biomarker Type
PSA
HER-2
EGFR
KRAS
Others
By End User
Pharmaceutical & Biotechnology Companies
Diagnostics & Research Laboratories
Hospitals & Specialty Clinics
Others
By Geography
North America (the U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America)
Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
- 4.2. New Product Launches, by Key Market Players
- 4.3. Pipeline Analysis, Cancer Biomarkers
- 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
- 5. Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Cancer Type
- 5.2.1. Lung Cancer
- 5.2.2. Breast Cancer
- 5.2.3. Colorectal Cancer
- 5.2.4. Prostate Cancer
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 5.3.1. PSA
- 5.3.2. HER-2
- 5.3.3. EGFR
- 5.3.4. KRAS
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By End User
- 5.4.1. Pharmaceutical & Biotechnology Companies
- 5.4.2. Diagnostics & Research Laboratories
- 5.4.3. Hospitals & Specialty Clinics
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Cancer Type
- 6.2.1. Lung Cancer
- 6.2.2. Breast Cancer
- 6.2.3. Colorectal Cancer
- 6.2.4. Prostate Cancer
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 6.3.1. PSA
- 6.3.2. HER-2
- 6.3.3. EGFR
- 6.3.4. KRAS
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By End User
- 6.4.1. Pharmaceutical & Biotechnology Companies
- 6.4.2. Diagnostics & Research Laboratories
- 6.4.3. Hospitals & Specialty Clinics
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Cancer Type
- 7.2.1. Lung Cancer
- 7.2.2. Breast Cancer
- 7.2.3. Colorectal Cancer
- 7.2.4. Prostate Cancer
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 7.3.1. PSA
- 7.3.2. HER-2
- 7.3.3. EGFR
- 7.3.4. KRAS
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By End User
- 7.4.1. Pharmaceutical & Biotechnology Companies
- 7.4.2. Diagnostics & Research Laboratories
- 7.4.3. Hospitals & Specialty Clinics
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Cancer Type
- 8.2.1. Lung Cancer
- 8.2.2. Breast Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Prostate Cancer
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 8.3.1. PSA
- 8.3.2. HER-2
- 8.3.3. EGFR
- 8.3.4. KRAS
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By End User
- 8.4.1. Pharmaceutical & Biotechnology Companies
- 8.4.2. Diagnostics & Research Laboratories
- 8.4.3. Hospitals & Specialty Clinics
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Cancer Type
- 9.2.1. Lung Cancer
- 9.2.2. Breast Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Prostate Cancer
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 9.3.1. PSA
- 9.3.2. HER-2
- 9.3.3. EGFR
- 9.3.4. KRAS
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By End User
- 9.4.1. Pharmaceutical & Biotechnology Companies
- 9.4.2. Diagnostics & Research Laboratories
- 9.4.3. Hospitals & Specialty Clinics
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Cancer Type
- 10.2.1. Lung Cancer
- 10.2.2. Breast Cancer
- 10.2.3. Colorectal Cancer
- 10.2.4. Prostate Cancer
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast – By Biomarker Type
- 10.3.1. PSA
- 10.3.2. HER-2
- 10.3.3. EGFR
- 10.3.4. KRAS
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By End User
- 10.4.1. Pharmaceutical & Biotechnology Companies
- 10.4.2. Diagnostics & Research Laboratories
- 10.4.3. Hospitals & Specialty Clinics
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 10.5.1. GCC Countries
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2018)
- 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.3.1. F. Hoffmann-La Roche Ltd.
- 11.3.1.1. Overview,
- 11.3.1.2. Products & services,
- 11.3.1.3. SWOT analysis,
- 11.3.1.4. Recent developments,
- 11.3.1.5. strategies,
- 11.3.1.6. financials (based on availability)
- 11.3.2. Abbott
- 11.3.2.1. Overview,
- 11.3.2.2. Products & services,
- 11.3.2.3. SWOT analysis,
- 11.3.2.4. Recent developments,
- 11.3.2.5. strategies,
- 11.3.2.6. financials (based on availability)
- 11.3.3. CENTOGENE N.V.
- 11.3.3.1. Overview,
- 11.3.3.2. Products & services,
- 11.3.3.3. SWOT analysis,
- 11.3.3.4. Recent developments,
- 11.3.3.5. strategies,
- 11.3.3.6. financials (based on availability)
- 11.3.4. Bio-Rad Laboratories, Inc.
- 11.3.4.1. Overview,
- 11.3.4.2. Products & services,
- 11.3.4.3. SWOT analysis,
- 11.3.4.4. Recent developments,
- 11.3.4.5. strategies,
- 11.3.4.6. financials (based on availability)
- 11.3.5. CENTOGENE N.V.
- 11.3.5.1. Overview,
- 11.3.5.2. Products & services,
- 11.3.5.3. SWOT analysis,
- 11.3.5.4. Recent developments,
- 11.3.5.5. strategies,
- 11.3.5.6. financials (based on availability)
- 11.3.6. Axon Medchem
- 11.3.6.1. Overview,
- 11.3.6.2. Products & services,
- 11.3.6.3. SWOT analysis,
- 11.3.6.4. Recent developments,
- 11.3.6.5. strategies,
- 11.3.6.6. financials (based on availability)
- 11.3.7. Sino Biological Inc.
- 11.3.7.1. Overview,
- 11.3.7.2. Products & services,
- 11.3.7.3. SWOT analysis,
- 11.3.7.4. Recent developments,
- 11.3.7.5. strategies,
- 11.3.7.6. financials (based on availability)
- 11.3.8. R&D System
- 11.3.8.1. Overview,
- 11.3.8.2. Products & services,
- 11.3.8.3. SWOT analysis,
- 11.3.8.4. Recent developments,
- 11.3.8.5. strategies,
- 11.3.8.6. financials (based on availability)
- 11.3.9. BioVision Inc.
- 11.3.9.1. Overview,
- 11.3.9.2. Products & services,
- 11.3.9.3. SWOT analysis,
- 11.3.9.4. Recent developments,
- 11.3.9.5. strategies,
- 11.3.9.6. financials (based on availability)
- 11.3.10. Myriad RBM
- 11.3.10.1. Overview,
- 11.3.10.2. Products & services,
- 11.3.10.3. SWOT analysis,
- 11.3.10.4. Recent developments,
- 11.3.10.5. strategies,
- 11.3.10.6. financials (based on availability)
- 11.3.11. Other Prominent Players
- 11.3.11.1. Overview,
- 11.3.11.2. Products & services,
- 11.3.11.3. SWOT analysis,
- 11.3.11.4. Recent developments,
- 11.3.11.5. strategies,
- 11.3.11.6. financials (based on availability)
- 12. Strategic Recommendation "
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook